Provider review
Embody Review: It Sells a GLP-1 Without Ever Naming the Drug
Embody sells weekly injections from $79 a month and will not tell you what is in them. Across its homepage the words semaglutide and tirzepatide appear zero times; the products are "GLP-1 Injections" and "GLP-1 / GIP Injections" — a receptor class, not a drug. The second narrows to tirzepatide by pharmacology, because it is the only marketed dual agonist. The first is genuinely open.
Of every company we track, Embody is the only one that will not tell you what drug it is selling you. Its two products are "GLP-1 Injections" at $79 a month and "GLP-1 / GIP Injections" at $129, and the words semaglutide and tirzepatide appear nowhere on its homepage. The second is identifiable by pharmacology — a dual agonist can only be tirzepatide — and to Embody's credit that implied pharmacology is correct, which is more than several better-known competitors manage. The first is genuinely ambiguous. Everything offered in place of that information is atmosphere: a promo banner saving "$200 instantly", a counter reporting that 400 people finished the intake today, "OUR STELLAR DOCTORS", and a single efficacy claim — "potential to lose pounds of fat every week" — describing a rate no trial has ever reported. The refund policy and the absence of a membership fee look genuine and are prominently placed. But a weekly injectable prescription whose active ingredient is not disclosed on the storefront is the lowest standard of disclosure in this entire review series.
Worth trusting if
- You want a price that does not climb as your dose does, because Embody states in its own FAQ that dose changes never change the bill.
- You want a phone number and a registered address before you buy, because Embody publishes both where several sellers here publish neither.
- You are comparing cash prices only, because the pay-monthly figure here is among the lowest we have walked and carries no membership fee on top.
Be skeptical if
- You need to know which drug you are injecting, because neither the storefront nor the checkout ever writes semaglutide or tirzepatide.
- You budget by the calendar month, because the monthly plan buys four weeks and the twelve-month plan buys 48.
- You are persuaded by the pace on the results screen, because no trial has reported the weekly loss it promises you.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens joinem.co. A link is not a recommendation to take anything.
Provenance
What Embody actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Weekly GLP-1 Injections — "Starting at $79/month", presented under a "Summer Start Promo Applied. Save $200 instantly" banner — so the figure shown is a promotional rate, and no standing price is published.
- Weekly GLP-1 / GIP Injections — "Starting at $129/month", under the same $200 promotional banner; no standing price is published.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to Embody.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Embody’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Weekly GLP-1 InjectionsSemaglutide or tirzepatide, named only as "GLP-1" · Compounded (503A)No trial supports this claim
“WEEKLY GLP-1 Injections — One simple injection once a week. No hidden fees, shipped to your door, starting at $79/month. […] Fat Loss made simple, powered by GLP-1 Science + Care. Potential to lose pounds of fat every week. Weight Loss Money Back Guarantee. No membership or hidden fees. HSA/FSA Approved. Guided by EXPERT clinicians.”
Read on the Embody site, August 2026
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the likeliest molecule behind an unnamed weekly "GLP-1", but Embody does not say.
The problem is not that the claim overstates a molecule's evidence — it is that Embody never says which molecule. "GLP-1 Injections" names a receptor class, and the words semaglutide and tirzepatide appear nowhere on the page. A patient cannot check a claim, look up a side-effect profile, compare a price or discuss an interaction without knowing what they are being prescribed, and the storefront withholds it. On top of that sits the site's only efficacy statement, and it is a RATE claim: "Potential to lose pounds of fat every week." No GLP-1 trial reports weekly fat loss as an endpoint; STEP 1 and SURMOUNT-1 measured total body-weight change over 68 and 72 weeks, with lifestyle intervention in every arm. A weekly rate implies a steadiness the trials do not describe and that early titration in particular does not produce.1
Weekly GLP-1 / GIP InjectionsTirzepatide, named only as "GLP-1 / GIP" · Compounded (503A)Claim reaches past the trials
“Weekly GLP-1 / GIP Injections — One simple injection once a week. No hidden fees, shipped to your door, starting at $129/month.”
Read on the Embody site, August 2026
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide over 72 weeks. "GLP-1 / GIP" identifies a dual agonist, and tirzepatide is the only one marketed — so the product is identifiable by pharmacology even though Embody never names it.
This one is at least identifiable: "GLP-1 / GIP" describes a dual agonist, and tirzepatide is the only dual agonist on the market, so a reader who knows the pharmacology can work out what it is. That is a lower bar than naming it, and it is the closest Embody comes. The pharmacology implied is correct — unlike two sellers we've reviewed that call tirzepatide a plain GLP-1 agonist and one that calls it an antagonist. What still reaches past the evidence is the site-wide framing it inherits: "Potential to lose pounds of fat every week", against trials that measured total weight change over 72 weeks with diet and activity support throughout.2
Dispensing chain
Who actually fills your prescription
Read the full account
No dispensing pharmacy is named, no compounding category is stated — neither 503A nor 503B appears — and, alone among the companies we track, the active ingredient is not named either. Embody's products are "GLP-1 Injections" and "GLP-1 / GIP Injections", which are receptor classes rather than drugs. That is a more fundamental gap than an unnamed pharmacy: a patient cannot look up a side-effect profile, check an interaction, compare a price against the market or have an informed conversation with another clinician without knowing which compound they are injecting weekly. The second product is identifiable by inference — "GLP-1 / GIP" describes a dual agonist and tirzepatide is the only one marketed — and the implied pharmacology is correct, which is more than two competitors manage. The first product is genuinely ambiguous. Clinical oversight is asserted only as "Guided by EXPERT clinicians" and "OUR STELLAR DOCTORS"; no medical group, no individual clinician and no license number is published anywhere.
Read on the Embody site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Nothing is published. No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup — and no pharmacy named to ask, no compounding category stated, and no active ingredient identified. Of every company we track, Embody is the only one where you cannot establish what the medication is, let alone who made it or whether the lot was tested. The trust signals offered in place of that are atmospheric rather than checkable: "Guided by EXPERT clinicians", "OUR STELLAR DOCTORS", "MARKET LEADING COST", "GLP-1 SCIENCE" as a navigation heading, and a live counter announcing that "400+ completed the intake today in under 2 mins". A counter that reports today's intake volume is a scarcity and social-proof device, not information about a medicine. No study, trial identifier or publication is cited anywhere on the site, either.
Read on the Embody site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Not published — no state list, inclusion or exclusion, appears anywhere on the site
Read the full licensing claim
Embody publishes no coverage information of any kind: no state list, no map, no exclusion notice and no per-product restriction. This review lists no excluded states, and that is because nothing has been disclosed — not because none exist. No medical group is named, no individual clinician is named and no license number is published; clinical oversight appears only as marketing — "Guided by EXPERT clinicians" and a nav item reading "OUR STELLAR DOCTORS". A telephone number, (347) 269-4270, is published, which is more than several competitors offer. Two commercial terms are prominent and appear to be genuine: "No membership or hidden fees" and a "100% REFUND POLICY" with a "Weight Loss Money Back Guarantee", both given their own navigation entries rather than buried. What is not published is the standing price those terms attach to — every figure on the page sits under a "Summer Start Promo Applied. Save $200 instantly" banner.
Read on the Embody site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Embody
We went through Embody’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Open the qualifying form from the homepage. Height, weight, goal weight, state, date of birth, sex and the whole condition checklist sit on one page.
- Read a fitness verdict built from your answers, then agree to a stated rate of weekly loss.
- Pick what you want the compound to do for you, then say whether affordability or potency matters more.
- Give a name, email and phone number. Two consent boxes are already ticked when the screen loads.
- The approval screen arrives with a countdown clock and the medication prices on it.
- Choose a treatment and a plan length, then enter a shipping address. We stopped at the card fields.
- $79 a month is the pay-monthly rate for the unnamed weekly GLP-1, falling to $76 on three months, $73 on six and $69 on twelve, each shown against a struck-through $299.
- The monthly plan is described as a four-week supply and the twelve-month plan as a 48-week supply, so both plan names are shorter than the calendar periods they borrow.
- The dual-agonist product is $129 on the homepage and $119 on the checkout screen. Neither page names the molecule.
- The results screen states a rate: with medication you will lose 3.75 to 5 pounds a week, and reach a goal 40 pounds away in about eight weeks. No trial of either molecule reports anything of the kind.
- The whole offer sits under a clock counting down from just under fifteen minutes, on a page headed with the word approved before any clinician has seen the answers.
- Both consent boxes on the details screen are pre-ticked, including the one agreeing to automated marketing texts and to a subscription that renews until canceled.
- The checkout page links four dispensing pharmacies by name — Red Rock Home Pharmacy, HealthWarehouse, MyPCP Health and Triad Rx — which the storefront never does.
- The promotional banner now reads that you save $230 every month, where it read a lower figure when this review was first written. No standing price is published either way.
Embody support
- Phone
- (347) 269-4270
Assessment
What holds up, and what does not
- "GLP-1 / GIP" correctly implies a dual agonist, which is the right pharmacology for tirzepatide — two sellers we've reviewed call it a plain GLP-1 agonist and one calls it an antagonist.
- "No membership or hidden fees" and a "100% refund policy" with a money-back guarantee are given their own navigation entries rather than buried in terms.
- A telephone number is published — (347) 269-4270 — which several competitors do not offer.
Show 4 more
- It sells only two products at two clearly different prices, so there is no confusing ladder of tiers to decode.
- HSA/FSA eligibility is stated up front.
- The whole site reads without JavaScript, unlike two other sellers we've reviewed, so nothing is hidden behind a script that fails to load.
- No FDA warning letter for Embody.
- It never names the active ingredient. "Semaglutide" and "tirzepatide" appear zero times on the homepage; the products are sold as "GLP-1 Injections" and "GLP-1 / GIP Injections".
- A patient cannot check a side-effect profile, an interaction or a market price without knowing which molecule they are being prescribed.
- "Potential to lose pounds of fat every week" is a rate claim. No GLP-1 trial reports weekly fat loss as an endpoint.
Show 8 more
- Every price sits under a "Summer Start Promo Applied. Save $200 instantly" banner, and no standing price is published.
- A live counter announces "400+ completed the intake today in under 2 mins" — a social-proof device rather than information.
- No dispensing pharmacy is named, and no compounding category — 503A or 503B — is stated.
- No certificate of analysis, lot number, potency or sterility result is published.
- No medical group, individual clinician or license number is named; clinical oversight appears only as "EXPERT clinicians" and "OUR STELLAR DOCTORS".
- No state coverage is published at all — no list, no map, no exclusions.
- No study, trial identifier or publication is cited anywhere.
- It sells no peptide beyond the two unnamed GLP-1s.
Verdict
The bottom line
Do not start an intake until Embody names the molecule in writing, because the storefront never does — and "GLP-1 Injections" could be more than one drug. What the page offers in place of that is atmosphere: a promo saving "$200 instantly" and a counter of completed orders, neither of which tells you what you would be injecting every week.
Opens joinem.co. A link is not a recommendation to take anything.
Two products, no drug
Here is Embody's whole catalog, as its homepage presents it:
"WEEKLY GLP-1 Injections — One simple injection once a week. No hidden fees, shipped to your door, starting at $79/month"
>
"Weekly GLP-1 / GIP Injections — One simple injection once a week. No hidden fees, shipped to your door, starting at $129/month"
Read those again for what is missing.
"GLP-1" is a receptor class, not a drug. Across Embody's homepage, the words semaglutide and tirzepatide appear zero times. A prospective patient is being offered a weekly injectable prescription and is not told what is in it.
That is a more basic gap than an unnamed pharmacy, which is the usual failure in this category. Without the molecule you cannot look up a side-effect profile, check an interaction against something else you take, compare the price against the market, or have a useful conversation with any other clinician.
The second product is at least inferable. "GLP-1 / GIP" describes a dual agonist, and tirzepatide is the only dual agonist on the market — so a reader who knows the pharmacology can work it out. And the implied pharmacology is right, which is worth crediting: two sellers we've reviewed describe tirzepatide as a plain GLP-1 receptor agonist, and one calls it an antagonist, which is the opposite of what it does.
The first product — "GLP-1 Injections", $79 a month — is genuinely open. It could be compounded semaglutide. Embody does not say.
Full analysis — 4 more sectionsThe one efficacy claim · What fills the space where the information should be · What is genuinely good · What this means if you are buying
The one efficacy claim
"Potential to lose pounds of fat every week"
This is the only statement on the site about what the medication does, and it is a rate claim.
No GLP-1 trial reports weekly fat loss as an endpoint. STEP 1 measured total body-weight change over 68 weeks, and SURMOUNT-1 over 72, with diet and activity support in every arm throughout. 1 2 Neither reports pounds of fat per week, and neither describes the steady linear progress that phrasing implies — least of all during the early titration months, when doses are still climbing.
"Potential to" is doing the hedging. What it hedges is a shape of result the trials do not describe.
What fills the space where the information should be
Embody's homepage navigation reads: "OUR TOP PRODUCTS · GLP-1 SCIENCE · WHAT TO EXPECT · MARKET LEADING COST · OUR STELLAR DOCTORS · 100% REFUND POLICY · FAQ · CONTACT US".
Across the page:
- A banner: "Summer Start Promo Applied. Save $200 instantly + Fast, Free Shipping!"
- A live counter: "400+ completed the intake today in under 2 mins"
- "Guided by EXPERT clinicians"
- "Weight Loss Money Back Guarantee"
- "AM I QUALIFIED?"
The counter is a social-proof and urgency device. It reports how many people finished a form today, which tells a reader nothing about a medicine.
"OUR STELLAR DOCTORS" is the site's entire disclosure about clinical oversight. No medical group is named. No individual clinician is named. No license number is published.
And every price on the page sits underneath the promo banner, so no standing price is published at all — $79 and $129 are promotional rates against an undisclosed regular one.
What is genuinely good
Two things, and they are not nothing.
The commercial terms are prominent and appear real. "No membership or hidden fees" and a "100% REFUND POLICY" with a money-back guarantee each get their own navigation entry rather than being buried in a terms page nobody opens. Plenty of sellers in this market hide their refund position or contradict it across documents.
A telephone number is published — (347) 269-4270 — which several competitors here do not provide.
And the site reads without JavaScript, unlike two other companies in this review series — nothing is hidden behind a script that fails to load.
What this means if you are buying
Before anything else, ask what the molecule is. Embody will not tell you on the storefront, and it is the first question — not because compounded semaglutide or tirzepatide is a bad thing to buy, but because you cannot evaluate a prescription you cannot name.
Then ask the questions this site asks everywhere: which pharmacy compounds it, under which category, and can you see a certificate of analysis. Embody publishes none of that, states no compounding category, and names no pharmacy.
Treat "potential to lose pounds of fat every week" as marketing. The trials behind these molecules measured total weight change over roughly a year and a half, alongside diet and activity support.
And find out what the price becomes when the Summer Start Promo ends, because the $79 and $129 on the page are not standing rates.
Questions
Frequently asked questions
What drug does Embody actually sell?
It does not say, and that is the central finding of this review. Its two products are listed as "GLP-1 Injections" at $79 a month and "GLP-1 / GIP Injections" at $129 — receptor classes rather than drugs — and the words semaglutide and tirzepatide appear zero times on its homepage. The second product is identifiable by inference: "GLP-1 / GIP" describes a dual agonist, and tirzepatide is the only dual agonist on the market. To Embody's credit that implied pharmacology is correct, where two competitors call tirzepatide a plain GLP-1 agonist and one calls it an antagonist. The first product is genuinely ambiguous. Ask before you buy: you cannot check a side-effect profile, an interaction or a market price for a prescription you cannot name.
Can you really lose pounds of fat every week?
No trial has reported that, and it is the only efficacy claim on Embody's site. The page says "Potential to lose pounds of fat every week", which is a claim about rate. The trials behind these molecules measured something different: STEP 1 tracked total body-weight change over 68 weeks and SURMOUNT-1 over 72, with diet and activity support in every arm, and neither reports weekly fat loss as an endpoint. A weekly rate also implies a steadiness the trials do not describe, particularly during the early months when the dose is still being titrated upward. "Potential to" hedges the promise; what it hedges is a shape of result that was never measured.
What does Embody cost?
$79 a month for its weekly GLP-1 injection and $129 for the GLP-1/GIP one — but both figures sit under a banner reading "Summer Start Promo Applied. Save $200 instantly", so they are promotional rates and no standing price is published anywhere on the site. In Embody's favor, "No membership or hidden fees" and a "100% refund policy" with a money-back guarantee are given their own navigation entries rather than buried in terms, and HSA/FSA eligibility is stated up front. Ask what the price becomes when the promotion ends before committing to a weekly injectable.
Who makes and prescribes Embody's medication?
Neither is disclosed. No dispensing pharmacy is named, no compounding category is stated — neither 503A nor 503B appears — and no certificate of analysis, lot number, potency or sterility result is published. On the clinical side, the site offers "Guided by EXPERT clinicians" and a navigation heading reading "OUR STELLAR DOCTORS"; no medical group, no individual clinician and no license number is named anywhere. Combined with the unnamed active ingredient, Embody is the only company in this review series where a prospective buyer cannot establish what the medication is, who made it, or who is prescribing it. A telephone number is published, (347) 269-4270, which is the one channel available for asking.
Glossary
Key terms
Show definitions
- GLP-1
- A receptor, and a class of drugs that activate it — not a specific medicine. Semaglutide, liraglutide and others are all GLP-1 receptor agonists with different dosing, durations and side-effect profiles.
- GLP-1 / GIP
- A dual agonist acting at both the GLP-1 and GIP receptors. Tirzepatide is currently the only marketed example, so the label identifies the molecule by implication even when the name is withheld.
- Social-proof counter
- A live figure reporting recent activity — here, "400+ completed the intake today". It creates urgency and tells a reader nothing about the medicine, its evidence or its safety.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Embody's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.